Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially the veins in the legs and pelvis.
Dyspnea, chest pain, syncope or tachypnea (respiratory rate of ≥20/min) occur in most cases of pulmonary embolism.
Pleuritic chest pain with or without dyspnea is one of the most frequent presentations of this disease.
Syncope or shock are the hallmark signs of central pulmonary embolism and usually result in severe hemodynamic repercussions.
Signs of hemodynamic compromise and reduced heart flow are also usually present.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH) may experience improvements in exercise capacity and other outcomes when treated with a continuous, subcutaneous, high dose of treprostinil, according to the phase III CTREPH* trial.
Transfusion of red blood cells (RBC) in patients hospitalized with acute pulmonary embolism (PE) is uncommon and may increase the risk of short- and long-term mortality, independent of haemoglobin (Hb) level on admission, suggests a study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.